Bruker Daltonics and Serva Electrophoresis Announce Release of Novel ICPL Triplex Protein Quantitation Technology for Expression Proteomics; Three Independent Entire Proteomes Can Now Be Quantified Simultaneously.

SEATTLE -- At the 2006 ASMS conference, Bruker Daltonics Inc. and Serva Electrophoresis GmbH today announce the release of an ICPL(TM) Triplex kit, based on stable isotope labeling technology which has now been further developed by Drs. Friedrich Lottspeich and Josef Kellermann at the Max-Planck-Institute of Biochemistry in Martinsried, Germany.

This novel technology enables true quantitative proteomics of three independent proteomes using Isotope Coded Protein Labels (ICPL), resulting in the identification of differentially expressed proteins in triplex analysis with an unmatched dynamic range due to the optional combination with intact protein fractionation steps. This is possible since, in contrast to other stable isotope labeling approaches, the ICPL labeling step is not limited to the peptide level but is applied already on the protein level. For complex proteomes, the complexity of the resulting peptide mixtures typically exceeds the capacity of 1D or 2D peptide chromatographic steps and requires reduction of complexity. As a unique feature, ICPL allows such reduction of complexity on the protein level by chromatographic or other fractionation steps without any sacrifice of quantitation accuracy. All lysine side chains are modified selectively and quantitatively by one of the three ICPL tags (L = (12)C(6)(1)H(4), M = (12)C(6)(2)D(4) and H = (13)C(6)(1)H(4)), introducing mass differences of 4 Da (M-L) and 6 Da (H-L) per labeled site. Thus, multiple peptides from each protein usually carry the ICPL-tags after proteolysis, which allows for robust statistical analysis. The ICPL chemistry also leads to the detection of modified peptides with further increased sensitivity in mass spectrometry.

The ICPL Triplex workflow is compatible with all established LC or gel based protein and peptide fractionation and separation techniques and with all mass spectrometer types on the market, including ion traps. Protein identification and quantitation can be obtained after protein digestion either with ESI-MS/MS on Bruker Daltonics' HCTultra ion trap or micrOTOF-Q Q-q-TOF system, or by using MALDI-MS/MS on the ultraflex II TOF/TOF. For mass spectrometric analysis of ICPL Triplex samples, WARP-LC 1.1 software is now available from Bruker Daltonics to enable multiplexed proteomics quantification. Through a co-marketing agreement between Bruker Daltonics and SERVA, the SERVA ICPL Triplex kit can also be purchased directly from Bruker Daltonics worldwide.

Dr. Detlev Suckau, Head of Proteomics Development at Bruker Daltonik GmbH in Germany, stated: "We consider the new ICPL Triplex labeling technology a breakthrough for true quantitation in proteomics and biomarker discovery. For the first time, three entire proteomes can be analyzed quantitatively simultaneously and using robust statistics, cutting down on protein pre-fractionation efforts significantly. The SERVA ICPL Triplex kit, in combination with our outstanding LC-ESI and LC-MALDI MS/MS instrumentation, represents a great step forward towards high-fidelity and high-content proteomics. We have used the ICPL kit already very successfully in this year's ABRF 2006 PRG quantification study on our instruments, and we are excited about this new triplex extension of the ICPL kit."

Barbara Mueller, SERVA Electrophoresis GmbH, Heidelberg, said: "SERVA, as a leading supplier of electrophoresis specialty products, is the exclusively licensed distributor of the unique ICPL Triplex kit. Under our co-marketing agreement with Bruker Daltonics, new application avenues are opened with clear benefits for proteomics users."

ICPL inventor Professor Friedrich Lottspeich, commented: "Key to the success of proteomics technology is that quantitative information on proteins can be obtained fast and reliably with a high dynamic range in order to access low abundant proteins. These are typically the proteins that matter. That absolutely requires proteome fractionation on the protein level, not only on the peptide level. The ICPL Triplex technology was designed to provide reliable quantitation due to data redundancy and compatibility with any combination of protein fractionation technologies, including one- or two-dimensional gel electrophoresis or protein LC. We are delighted that this powerful technology will now be made available to the scientific community".

ASMS 2006, the 54th American Society for Mass Spectrometry Conference will be held May 28 - June 1, 2006 in Seattle, Washington in the Washington State Convention & Trade Center.

ABOUT SERVA ELECTROPHORESIS GMBH

SERVA Electrophoresis GmbH is an independent company with offices in Heidelberg and Uetersen. Germany. SERVA is committed to supply top quality reagents and specialty products through a global distribution network. SERVA's mission is to provide innovative products, e.g., for protein analytics and proteome research, originating from know-how in electrophoresis available at SERVA for decades, and through collaborations with partners. Certified ISO 9001:2000, SERVA has a commitment to adapt to the changing needs of scientists and to sustain consistent product quality and supply.

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC) detection products for defense and homeland security. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.